Cerebrolysin regulatory status
Current status of Cerebrolysin in the United States: Unscheduled. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of Cerebrolysin?
Regulatory: UnscheduledWADA: Not WADA prohibitedVerified: Verified Sep 29, 2026
- FDA and compounding
- Cerebrolysin is not an FDA approved drug, and no FDA approval or marketing application has been identified. As of the last verification date, it did not appear on any FDA 503A category list (Category 1, 2, 3 or the withdrawn list) or on the 503A bulks list. No USP monograph or approved drug containing it has been identified. That leaves it outside FDA's interim enforcement policy, with no identified lawful basis for a US compounding pharmacy to prepare it. Whether FDA treats this animal-brain-derived peptide mixture as a biological product is unconfirmed.
- WADA
- Not WADA prohibited
- Access path
- Not legally available in the United States: no FDA approved product and no compounding pathway.
- Prescription in countries where it is registered (Austria, Russia, China, and others), administered by infusion in a clinic.
- Products imported or sold online for US use are unapproved drugs and are not verified for cold chain or authenticity.
Full Cerebrolysin page: evidence, dosing in the literature, and sources
How has the status of Cerebrolysin changed over time?
No dated regulatory event has been recorded for Cerebrolysin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Cerebrolysin and the source of each dated event.
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [4]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026